PriceTargets.com logo

TerrAscend - TRSSF Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.64 As of 04/24/2024 01:00 AM ET
▼ -0.05 (-2.96%)

This chart shows the closing price for TRSSF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TerrAscend Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRSSF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRSSF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for TerrAscend in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.64.

This chart shows the closing price for TRSSF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in TerrAscend. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/4/2023Atb Cap MarketsReiterated RatingOutperform
6/30/2023Craig HallumUpgradeHold ➝ Buy
5/19/2023Needham & Company LLCDowngradeBuy ➝ Hold
3/17/2023Needham & Company LLCReiterated RatingBuy$1.75
2/8/2023Stifel NicolausLower TargetC$5.50 ➝ C$4.50
10/28/2022Cantor FitzgeraldLower TargetNeutral$2.85 ➝ $2.15
9/12/2022Canaccord Genuity GroupInitiated CoverageBuyC$4.25
8/15/2022CowenLower Target$9.00 ➝ $4.50
8/12/2022Stifel NicolausLower TargetC$6.00 ➝ C$5.50
8/12/2022Craig HallumDowngradeBuy ➝ Hold$7.50 ➝ $2.00
8/12/2022Needham & Company LLCLower TargetBuy$4.00 ➝ $3.00
8/12/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
7/22/2022Seaport Res PtnReiterated RatingBuy
5/13/2022Echelon Wealth PartnersReiterated RatingHold
3/17/2022Clarus SecuritiesReiterated RatingBuy
3/17/2022Needham & Company LLCInitiated CoverageBuy$8.00
3/17/2022Cantor FitzgeraldBoost TargetOverweight$7.65 ➝ $7.90
3/16/2022Atb Cap MarketsReiterated RatingOutperform
12/8/2021Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$6.70 ➝ $7.65
11/17/2021Stifel NicolausLower TargetBuyC$23.00 ➝ C$21.00
11/3/2021Cantor FitzgeraldLower TargetOverweight$8.65 ➝ $6.70
11/1/2021Stifel NicolausLower TargetBuyC$25.00 ➝ C$23.00
9/23/2021Cantor FitzgeraldLower TargetOverweight$10.50 ➝ $8.65
8/20/2021Craig HallumLower TargetTop Pick ➝ Buy$21.50 ➝ $13.50
8/20/2021CowenLower TargetOutperform$13.00 ➝ $9.00
7/27/2021Needham & Company LLCLower TargetBuy$17.75 ➝ $17.00
7/7/2021Jefferies Financial GroupInitiated CoverageBuy$17.00
4/15/2021CowenInitiated CoverageOutperform
3/24/2021Needham & Company LLCBoost TargetBuy$17.50 ➝ $17.75
3/24/2021Cantor FitzgeraldLower TargetOverweight$21.00 ➝ $16.00
2/25/2021Stifel NicolausBoost TargetBuy$12.50 ➝ $24.00
2/19/2021Clarus SecuritiesBoost TargetBuy$18.75 ➝ $20.00
2/9/2021Craig HallumBoost TargetBuy$10.50 ➝ $20.00
1/19/2021Needham & Company LLCBoost TargetBuy$11.75 ➝ $17.50
1/8/2021Cantor FitzgeraldInitiated CoverageOverweight
12/21/2020Beacon SecuritiesBoost Target$13.50
12/18/2020Needham & Company LLCBoost Target$9.50 ➝ $11.50
12/16/2020Clarus SecuritiesInitiated CoverageBuyC$12.75 ➝ C$13.50
11/2/2020Needham & Company LLCBoost TargetBuy ➝ Buy$5.50 ➝ $7.50
8/25/2020Needham & Company LLCInitiated CoverageBuy$5.50
8/7/2020Stifel NicolausBoost TargetBuy$4.75 ➝ $6.50
7/22/2020Stifel NicolausInitiated CoverageBuy
6/15/2020LADENBURG THALM/SH SHInitiated CoverageBuy
6/8/2020Craig HallumInitiated CoverageBuy
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
TerrAscend logo
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis-infused artisan edibles. It also operates retail dispensaries under the Apothecarium brand name in California, Pennsylvania, and New Jersey. In addition, the company owns various synergistic businesses under Gage Growth, Pinnacle, TerrAscend NJ, Ilera Healthcare, HMS Health and HMS Processing, Valhalla Confections, State Flower, Arise Bioscience Inc., and TerrAscend Canada brands. It serves medical and legal adult-use markets. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $1.64
Low: $1.45
High: $1.70

50 Day Range

MA: $1.77
Low: $1.54
High: $2.07

52 Week Range

Now: $1.64
Low: $1.62
High: $1.80

Volume

533,621 shs

Average Volume

131,026 shs

Market Capitalization

$413.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.89

Frequently Asked Questions

What sell-side analysts currently cover shares of TerrAscend?

The following equities research analysts have issued reports on TerrAscend in the last twelve months: Atb Cap Markets, Craig Hallum, and Needham & Company LLC.
View the latest analyst ratings for TRSSF.

What is the current price target for TerrAscend?

0 Wall Street analysts have set twelve-month price targets for TerrAscend in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for TerrAscend in the next year.
View the latest price targets for TRSSF.

What is the current consensus analyst rating for TerrAscend?

TerrAscend currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TRSSF.

What other companies compete with TerrAscend?

Other companies that are similar to TerrAscend include TerrAscend, Grown Rogue International, Community Health Systems, ADC Therapeutics and Larimar Therapeutics. Learn More about companies similar to TerrAscend.

How do I contact TerrAscend's investor relations team?

TerrAscend's physical mailing address is PO Box 43125, Mississauga, ON L5B. The company's listed phone number is (855) 837-7295 and its investor relations email address is [email protected]. The official website for TerrAscend is www.terrascend.com. Learn More about contacing TerrAscend investor relations.